ワクチンの世界市場2016-2020

◆英語タイトル:Global Human Vaccine Market 2016-2020
◆商品コード:IRTNTR8142
◆発行会社(調査会社):Technavio
◆発行日:2016年1月20日
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、ワクチンの世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、ワクチンの世界市場規模及び予測、種類別分析、投与経路(ROA)別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Human Vaccine

According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a person’s immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose.

Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases.

Technavio’s analysts forecast the global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines.

The market is divided into the following segments based on geography:
• Americas
• APAC
• Europe

Technavio’s report, Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline
• Merck
• Pfizer
• Sanofi

[Other prominent vendors]
• Abbott
• AstraZeneca
• Bavarian Nordic
• Baxter
• Bharat Biotech
• Bharat Immunologicals and Biologicals
• bioCSL
• Bio Med
• Crucell
• Dynavax Technologies
• Indian Immunologicals
• Janssen Pharmaceuticals
• Kaketsuken
• LG Life Sciences
• Mitsubishi Tanabe Pharma
• Lupin
• Nuron
• Novartis
• Protein Sciences Corporation
• Panacea Biotec
• Roche
• Serum Institute of India
• Shenzhen Kangtai Biological Products
• Sinovac Biotech
• S K Chemicals
• Takeda Pharmaceutical
• Valeant Pharmaceuticals
• Zydus Cadila

[Market driver]
• Growing awareness about vaccination and immunization programs
• For a full, detailed list, view our report

[Market challenge]
• Inadequate vaccination coverage
• For a full, detailed list, view our report

[Market trend]
• Increase in strategic alliance and M&A
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Vaccine approval process
• Vaccines price list

PART 06: Pipeline portfolio

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type of human vaccine
• Live attenuated vaccine
• Killed vaccine
• Toxoid vaccine
• Genetically modified/engineered vaccine
• Synthetic vaccines
• Dendritic cells vaccines
• Conjugate vaccines
• Subunit vaccines

PART 09: Market segmentation by composition
• Mono vaccine
• Combination vaccines

PART 10: Market segmentation by route of administration
• Oral vaccines
• Intramuscular vaccines
• Intranasal vaccines
• Intradermal vaccines

PART 11: Market segmentation by type of human vaccine

PART 12: Global therapeutic human vaccines market
• Market overview
• Market size and forecast

PART 13: Global preventable human vaccines market
• Market overview
• Market size and forecast

PART 14: Global pediatric preventable human vaccines market
• Market size and forecast

PART 15: Global adult preventable human vaccines market
• Market size and forecast

PART 16: Geographical segmentation
• Human vaccines market in the Americas
• Market size and forecast
• Human vaccines market in EMEA
• Market size and forecast
• Human vaccines market in APAC
• Market size and forecast

PART 17: Market drivers
• Growing awareness about vaccination and immunization programs
• Inclusion in national immunization schedule
• High demand for pediatric vaccines
• Increase in prevalence of infectious diseases

PART 18: Impact of drivers

PART 19: Market challenges
• Inadequate vaccination coverage
• Vaccine storage and handling issues
• High risk associated with vaccine development
• Stringent regulatory process
• Misperception about vaccines
• Adverse side effects of vaccines

PART 20: Impact of drivers and challenges

PART 21: Market trends
• Increase in strategic alliance and M&A
• Entry of novel vaccines
• Increase in investment
• Focus on emerging markets
• Emergence of resistant strains
• Public-private initiatives

PART 22: Vendor landscape
• Competitive scenario

PART 23: Key vendor analysis
• GSK
• Sanofi
• Merck
• Pfizer
• Other prominent vendors

PART 24: Appendix
• List of abbreviations

PART 25: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Requirements for BLA submission in the US
Exhibit 03: Developmental steps required to reach the vaccine licensing stage
Exhibit 04: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
Exhibit 05: Regulatory testing of licensed vaccines
Exhibit 06: Pediatric/VFC vaccine price list
Exhibit 07: Pediatric influenza vaccine price list
Exhibit 08: Adult vaccine price list
Exhibit 09: Adult influenza vaccine price list
Exhibit 10: GlaxoSmithKline: Vaccine pipeline
Exhibit 11: Novartis: Vaccine pipeline
Exhibit 12: Merck: vaccine pipeline
Exhibit 13: Pfizer: vaccine pipeline
Exhibit 14: Sanofi: vaccine pipeline
Exhibit 15: TuBerculosis Vaccine Initiative (TBVI): vaccine pipeline
Exhibit 16: Some pipeline compounds under development in 2015
Exhibit 17: Top 10 pharmaceutical companies based on global vaccine revenues in 2014 ($ millions)
Exhibit 18: Global human vaccines market 2015-2020 ($ billions)
Exhibit 19: SWOT analysis
Exhibit 20: Five forces analysis
Exhibit 21: Global human vaccines market segmentation by type of vaccine
Exhibit 22: Examples of vaccines by type
Exhibit 23: Global human vaccines market segmentation by composition
Exhibit 24: Global human vaccines market segmentation by route of administration
Exhibit 25: Route of administration for different vaccines
Exhibit 26: Global human vaccines market types
Exhibit 27: Global preventable and therapeutic human vaccines market share 2015
Exhibit 28: Global therapeutic human vaccines market 2015-2020 ($ billions)
Exhibit 29: Global preventable human vaccines market 2015-2020 ($ billions)
Exhibit 30: Global preventable human vaccines market categories
Exhibit 31: Global pediatric and adult preventable human vaccines market share 2015
Exhibit 32: Global pediatric preventable human vaccines market segmentation 2015
Exhibit 33: Global pediatric preventable human vaccines market 2015-2020 ($ billions)
Exhibit 34: Global adult preventable human vaccines market share 2015
Exhibit 35: Global adult preventable human vaccines market 2015-2020 ($ billions)
Exhibit 36: Global human vaccines market by geography 2015
Exhibit 37: Global human vaccines market by region 2015-2020 ($ billions)
Exhibit 38: Human vaccines market in the Americas 2015-2020 ($ billions)
Exhibit 39: Human vaccines market in EMEA 2015-2020 ($ billions)
Exhibit 40: Human vaccines market in APAC 2015-2020 ($ billions)
Exhibit 41: Impact of drivers
Exhibit 42: Global immunization coverage 2014
Exhibit 43: A typical cold chain process
Exhibit 44: Adverse effects associated with some preventable human vaccines
Exhibit 45: Impact of drivers and challenges
Exhibit 46: M&A in the vaccine industry
Exhibit 47: Overview of major vaccine-related acquisitions (2005-2012)
Exhibit 48: Market share analysis of top pharma vaccine companies, 2014
Exhibit 49: GSK: Business segmentation by revenue 2014
Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 51: GSK: Geographical segmentation by revenue 2014
Exhibit 52: GSK: YoY revenue growth of Infanrix/Pediarix 2012-2014 ($ millions)
Exhibit 53: GSK: YoY revenue growth of Hepatitis vaccine 2012-2014 ($ millions)
Exhibit 54: GSK: YoY revenue growth of Synflorix 2012-2014 ($ millions)
Exhibit 55: GSK: YoY revenue growth of Rotarix 2012-2014 ($ millions)
Exhibit 56: GSK: YoY revenue growth of Boostrix 2012-2014 ($ millions)
Exhibit 57: GSK: Meningitis vaccine revenue 2013 and 2014 ($ millions)
Exhibit 58: GSK: Travel and paediatrics vaccine revenue 2013 and 2014 ($ millions)
Exhibit 59: Key takeaways
Exhibit 60: Sanofi: Business segmentation by revenue 2014
Exhibit 61: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 62: Sanofi: Geographical segmentation by revenue 2014
Exhibit 63: Sanofi: YoY revenue growth of Polio/pertussis/Hib vaccines ($ millions)
Exhibit 64: Sanofi: YoY revenue growth of influenza vaccines 2012-2014 ($ millions)
Exhibit 65: Sanofi: YoY revenue growth of meningitis/pneumonia vaccine 2012-2014 ($ millions)
Exhibit 66: Sanofi: YoY revenue growth of adult booster vaccine 2012-2014 ($ millions)
Exhibit 67: Sanofi: YoY revenue growth of travel and other endemic vaccines 2012-2014 ($ millions)
Exhibit 68: Key takeaways
Exhibit 69: Merck: Business segmentation by revenue 2014
Exhibit 70: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 71: Merck: Geographical segmentation by revenue 2014
Exhibit 72: Merck: YoY revenue growth of Gardasil 2012-2014 ($ millions)
Exhibit 73: Merck: YoY revenue growth of ProQuad/MMR II/Varivax 2012-2014 ($ millions)
Exhibit 74: Merck: YoY revenue growth of Zostavax 2012-2014 ($ millions)
Exhibit 75: Merck: YoY revenue growth of Pneumovax 23 2012-2014 ($ millions)
Exhibit 76: Merck: YoY revenue growth of RotaTeq 2012-2014 ($ millions)
Exhibit 77: Key takeaways
Exhibit 78: Pfizer: Business segmentation by revenue 2014 0
Exhibit 79: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions) 1
Exhibit 80: Pfizer: Geographical segmentation by revenue 2014 2
Exhibit 81: Pfizer: YoY revenue growth of Prevnar family 2012-2014 ($ millions) 3
Exhibit 82: Key takeaways



【掲載企業】

GlaxoSmithKline, Merck, Pfizer, Sanofi, Abbott, AstraZeneca, Bavarian Nordic, Baxter, Bharat Biotech, Bharat Immunologicals and Biologicals , bioCSL, Bio Med, Crucell, Dynavax Technologies, Indian Immunologicals, Janssen Pharmaceuticals, Kaketsuken, LG Life Sciences, Mitsubishi Tanabe Pharma, Lupin, Nuron, Novartis, Protein Sciences Corporation, Panacea Biotec, Roche, Serum Institute of India, Shenzhen Kangtai Biological Products, Sinovac Biotech, S K Chemicals, Takeda Pharmaceutical, Valeant Pharmaceuticals, Zydus Cadila.

【レポートのキーワード】

人間用ワクチン、弱毒生ワクチン、死菌ワクチン、トキソイドワクチン、合成ワクチン、治療ワクチン、予防ワクチン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[ワクチンの世界市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。H&I文字はH&Iグローバルリサーチ株式会社の商標(登録第5783645号)です。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。
※当サイトでは2016年05月27日現在 190,338 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆